Coronavirus Vaccine Update, May 26
We have a lot more vaccine news to catch up on, and I’ll use this as a new “frontrunning vaccine candidates” post, replacing this one (and updates therein) from about a month back. That one will give...
View ArticleCalculating Your Way to Antivirals
My intent is to start mixing in some non-coronavirus posts along with my pandemic science coverage – you know, like the blog used to be way back earlier in the year (!) Today’s subject might be a good...
View ArticleFormulating RNA – And Owning It
Headlines appeared last night about Moderna losing a patent case that affects its coronavirus vaccine work. I know from long experience on this blog that any discussion of patent and IP issues has an...
View ArticleThe Latest Repurposing News (Two Parter: IL-6 and Apilimod)
As everyone knows, there have been a lot of attempts to repurpose existing therapies for the coronavirus pandemic. I’ve covered several of these along the way, but it’s time for some updates. The work...
View ArticleClik here to view.
Coronavirus Challenges in Primates, Compared
We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try to compare them. I have worked up a table with all...
View ArticleStock Cults and the Coronavirus
Let’s take a few minutes to talk about biopharma stocks in general – or to be more precise, about some of the people who invest in biopharma stocks. There’s a lot of weird behavior in this area, and...
View ArticleDrug Repurposing: How Often Does It Work?
Here’s an article that will not be popular among some constituencies. It’s in a special issue of the Journal of Chemical Information and Modeling, devoted to how these disciplines have responded to...
View ArticleThe Big Problems
I’ve had a lot of people ask me about yesterday’s protein folding news as it relates to drug discovery. And while I did a post on that last year, I thought it might be useful to briefly lay out the...
View ArticleDrug Approvals Over the Last Ten Years
Here’s a look back at the last ten years of FDA drug approvals, and it’s a pretty encouraging read. As the authors mention, in the early 2000s there was quite a bit of worry about the directions that...
View ArticleAI and Drug Discovery: Attacking the Right Problems
I’ve been meaning to write some more about artificial intelligence, machine learning, and drug discovery, and this paper (open access) by Andreas Bender is an excellent starting point. I’m going to be...
View Article
